Hollow PtCo alloy nanospheres as a high-
Animals
Carcinoma, Non-Small-Cell Lung
/ radiotherapy
Catalase
/ metabolism
Cell Line, Tumor
Cobalt
/ chemistry
Humans
Lung Neoplasms
/ radiotherapy
Metal Nanoparticles
/ chemistry
Mice
Mice, Inbred C57BL
Microscopy, Electron, Transmission
Nanospheres
/ chemistry
Oxygen
/ metabolism
Platinum
/ chemistry
Powder Diffraction
Xenograft Model Antitumor Assays
Journal
Journal of materials chemistry. B
ISSN: 2050-7518
Titre abrégé: J Mater Chem B
Pays: England
ID NLM: 101598493
Informations de publication
Date de publication:
16 06 2021
16 06 2021
Historique:
pubmed:
20
5
2021
medline:
15
9
2021
entrez:
19
5
2021
Statut:
ppublish
Résumé
Radiotherapy, as well as chemotherapy and surgery, occupies an essential position in tumor treatment. Nonetheless, insufficient radiation deposition and hypoxia-related radioresistance of cancer cells still are serious challenges in radiotherapy. Herein, we proposed a hollow PtCo nanosphere (PtCo NS)-based novel radiosensitizer with three advantages to sensitize tumor radiotherapy: (i) the high-Z element Pt ensured higher radiation absorption to cause more DNA damage, (ii) the platinum (Pt) and cobalt (Co) elements exhibited a dual catalase-like enzymatic activity to convert endogenic H2O2 to O2 efficiently, and (iii) the unique hollow nature of the PtCo NS provided a large specific surface area, which could amplify the catalytic reaction of H2O2 to induce reactive oxygen species and cancer cell apoptosis upon combination with radiation. Both in vivo and in vitro studies showed that the hollow PtCo NS could significantly inhibit tumor growth, simultaneously relieving tumor hypoxia with good biocompatibility and biosafety. This work presents a simple but multifunctional radiosensitizer with a unique hollow structure for radiotherapy enhancement.
Substances chimiques
Cobalt
3G0H8C9362
Platinum
49DFR088MY
Catalase
EC 1.11.1.6
Oxygen
S88TT14065
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM